Navigation Links
Halozyme to Present New Data on PEGPH20 in Pancreatic Cancer at European Cancer Congress
Date:9/12/2013

SAN DIEGO, Sept. 12, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that clinical data from a Phase 1b trial of PEGPH20 (PEGylated recombinant human hyaluronidase) in combination with gemcitabine for the treatment of patients with stage IV metastatic pancreatic cancer will be presented at the European Cancer Congress 2013 (ECCO-ESMO-ESTRO) in Amsterdam. Additional data, including progression free and overall survival by hyaluronan (HA) status, will be presented at a poster session.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

Halozyme Poster Presentation at ECCO-ESMO-ESTRO:

  • "A Phase 1b study of gemcitabine plus PEGPH20 (PEGylated recombinant human hyaluronidase) in patients with stage IV previously untreated pancreatic cancer" will be presented by Joy Zhu M.D., Ph.D., Vice President, Oncology Clinical Development, Halozyme on Monday, September 30 in Hall 4 at 14:00 CEST. (Abstract #2598)

A Phase 2 multicenter, randomized clinical trial evaluating PEGPH20 in combination with nab-paclitaxel and gemcitabine for the treatment of stage IV pancreatic cancer began in April 2013. Approximately 124 patients are expected to participate in the trial and receive gemcitabine and nab-paclitaxel either with or without PEGPH20. Halozyme is also developing an HA diagnostic tool for use in the Phase 2 study to evaluate potential treatment benefit based on tumor HA levels. This HA-diagnostic approach may also enable the testing of PEGPH20 in other HA-rich tumor types.

About PEGPH20
Emerging data show that most pancreatic cancers surround themselves with a protective hyaluronan-rich matrix, which makes the di
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Halozyme Announces Roche Receives Marketing Authorization for Herceptin SC in European Union
2. Halozyme Reports Second Quarter 2013 Financial Results
3. Halozyme Provides Update on ViroPharma Phase 2 Trial of Subcutaneous Cinryze (C1 Esterase Inhibitor [Human]) Formulation with rHuPH20
4. Halozyme to Host Second Quarter 2013 Financial Results Conference Call
5. Halozymes Phase 1b Clinical Trial Of PEGPH20 With Gemcitabine Indicates Positive Activity Against Pancreatic Cancer
6. Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer
7. Halozyme Reports First Quarter 2013 Financial Results
8. Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference
9. Halozyme Therapeutics Names Matt Posard to Board of Directors
10. Baxter And Halozyme Announce Positive Opinion For HyQvia For Treatment Of Primary And Secondary Immunodeficiencies In The European Union
11. Halozyme Therapeutics to Present at the Barclays 2013 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb the ... ambulances and other transport vehicles, an advanced and portable UV germicidal ... for the first time. In order to prevent ... deadly pathogens, West Palm Beach Fire Rescue ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that ... available in its catalogue: ... for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
(Date:4/23/2014)... of endogenous neural precursor cells cannot alone compensate ... the perspective of neural plasticity, Dr. Yun Xiang ... observed the effects of functional electrical stimulation treatment ... of basic fibroblast growth factor and epidermal growth ... side. The researchers found that functional electrical stimulation ...
(Date:4/22/2014)... decades researchers have characterized a set of clock genes ... all types of species, from flies to humans. Over ... surmise there are more. A team from the Perelman ... if big-data approaches could find them. , To ... PhD, professor of Pharmacology and first author Ron Anafi, ...
(Date:4/22/2014)... Bethesda, MD, April 22, 2014: The Association for ... The Journal of Molecular Diagnostics on ... the baccalaureate and master,s levels of education. The ... (MLS) Curriculum Task Force of the AMP Training ... the critical need of educating future medical laboratory ...
(Date:4/22/2014)... April 2014. The latest scientific advances and emerging therapies ... 2014, the main annual meeting of the Heart Failure ... Journalists will also hear breaking news on acute heart ... Failure, which is part of the main congress. , ... Greece, at the Megaron Athens International Conference Centre (MAICC). ...
(Date:4/22/2014)... researchers have demonstrated the first size-based form of ... membranes of living cells. This unique physical approach ... critical to whether a cell lives or dies, ... obtained through conventional microscopy. , "We,ve developed membrane-embedded ... to both probe and manipulate membrane assemblies, including ...
Breaking Medicine News(10 mins):Health News:Bioinformatics profiling identifies a new mammalian clock gene 2Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2Health News:The world's largest heart failure congress 2Health News:The world's largest heart failure congress 3Health News:First size-based chromatography technique for the study of livi 2Health News:First size-based chromatography technique for the study of livi 3
... 23 Nordic Omega-3 Fishies is Nordic Naturals newest product ... fun shape and great tasting natural tangerine flavor. Perfect for ... made with purified fish oil from anchovies and sardines, two ... gram Omega-3 Fish contains 455 mg of fish oil and ...
... 23 The European diabetes diagnostics market is poised ... (POC) tests offering tremendous growth potential. Heightened efforts to ... a key driver in market development. For instance, limited ... However, this challenge will be curtailed with more education ...
... ... , ... 23, 2009 -- Big Case Marketing, the global leader in marketing for dentists, dental marketing ... a Boston based coaching and consulting firm for dentists with advanced clinical training, has announced ...
... ... other FL health insurance options. , ... Miami, FL (PRWEB) June 20, 2009 -- Get Online Quotes, an ... Miami Dade Blue ( http://www.getonlinequotes.com/miami-dade-blue.html ) by Blue Cross Blue Shield of Florida. ...
... (ASX: CYT) announced today that it has filed an Investigational ... Administration (FDA) for its novel, potent orally active JAK2 inhibitor ... intends to commence a Phase I/II trial for CYT387 in ... scar tissue develops in the bone marrow. CYT387 is expected ...
... ANGELES, June 22 Mission Viejo general surgeon ... Chair of the Mutual Protection Trust (MPT) Board of Trustees. ... of American Physicians, Inc. (CAP). Dr. Cobo,s election occurred at ... Wormley, MD, a Glendora family practitioner who presided as chair ...
Cached Medicine News:Health News:Nordic Omega-3 Fishies from Nordic Naturals Offers Quality EPA and DHA for Children with 'Kid Pleasin' Taste 2Health News:Frost & Sullivan: Self-Monitoring and POC Diabetes Tests Reveal Potential for Significant Growth, Boosting the European Diabetes Diagnostics Market 2Health News:Frost & Sullivan: Self-Monitoring and POC Diabetes Tests Reveal Potential for Significant Growth, Boosting the European Diabetes Diagnostics Market 3Health News:One of a Kind Marketing and Sales Summit for Dentists Announced 2Health News:One of a Kind Marketing and Sales Summit for Dentists Announced 3Health News:Get Online Quotes Offers "Miami Dade Blue", A Blue Cross Blue Shield Plan As Part of Their Florida Health Insurance Offerings 2Health News:Get Online Quotes Offers "Miami Dade Blue", A Blue Cross Blue Shield Plan As Part of Their Florida Health Insurance Offerings 3Health News:Cytopia Lodges IND for JAK2 Inhibitor CYT387 2Health News:Dr. Juan Carlos Cobo Newly-Elected Chair of the Mutual Protection Trust Board of Trustees 2
... has been designed specifically for the ... involved in ward rounds. It is ... dosages, and consultations that are requested ... Registrar during Ward round examinations and ...
... tracking and billing. This ... Handheld application, a complete ... CPT™ and ICD-9-CM codes ... Designed for any medical ...
In addition to the patient data OB-on-Call contains a comprehensive Medications list displaying related drugs by brand name, generic title, and usage description notes....
Archimedes is an innovative specialty calculator. Forget having to remember complicated formulas, just enter the values and out come the results....
Medicine Products: